| | Title | Authors / Editors | Date |
|
unige:79601 |
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects |
Toledo, Jon B.; Zetterberg, Henrik; van Harten, Argonde C.; Glodzik, Lidia; ... Trojanowski, John Q. |
2015 |
|
unige:138511 |
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study |
van Maurik, Ingrid S; Vos, Stephanie J; Bos, Isabelle; Bouwman, Femke H; ... van der Flier, Wiesje M |
2019 |
|
unige:112289 |
Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework |
Mattsson, Niklas; Lönneborg, Anders; Boccardi, Marina; Blennow, Kaj; Hansson, Oskar |
2017 |
|
unige:95511 |
Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient? |
Frisoni, Giovanni; Hansson, Oskar |
2016 |
|
unige:111281 |
Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations |
Lautner, Ronald; Insel, Philip S; Skillbäck, Tobias; Olsson, Bob; ... Zetterberg, Henrik |
2017 |
|
unige:151586 |
The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update |
Boccardi, Marina; Dodich, Alessandra; Albanese, Emiliano; Gayet-Ageron, Angèle; ... Garibotto, Valentina |
2021 |
Hansson, Oskar
add all
remove all
